Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLACNASDAQ:IRIXNASDAQ:PETVNASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLACBellevue Life Sciences Acquisition$1.21-3.2%$1.57$3.01▼$13.40$4.89M-0.0818,766 shs43,986 shsIRIXIRIDEX$1.00$1.04$0.78▼$2.79$16.79M0.6946,059 shs80,818 shsPETVPetVivo$0.79-7.7%$0.58$0.29▼$0.98$19.31M0.7820,089 shs13,835 shsVVOSVivos Therapeutics$3.06+0.7%$2.80$1.91▼$6.28$18.02M7.31450,948 shs90,972 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLACBellevue Life Sciences Acquisition-3.20%-8.33%-15.97%-82.76%-88.71%IRIXIRIDEX-9.09%-13.04%+1.01%-33.77%-67.53%PETVPetVivo+8.63%+39.61%+56.51%+26.47%+26.49%VVOSVivos Therapeutics-3.18%+11.36%+35.11%-28.47%+22.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIRIXIRIDEX0.8161 of 5 stars0.04.00.00.02.61.70.0PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/AVVOSVivos Therapeutics2.5512 of 5 stars3.55.00.00.02.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLACBellevue Life Sciences Acquisition 0.00N/AN/AN/AIRIXIRIDEX 0.00N/AN/AN/APETVPetVivo 0.00N/AN/AN/AVVOSVivos Therapeutics 3.00Buy$6.1099.35% UpsideCurrent Analyst Ratings BreakdownLatest BLAC, PETV, VVOS, and IRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/AIRIXIRIDEX$48.67M0.34N/AN/A$0.59 per share1.69PETVPetVivo$1.05M18.46N/AN/A($0.03) per share-26.46VVOSVivos Therapeutics$15.03M1.20N/AN/A$0.22 per share13.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLACBellevue Life Sciences AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AIRIXIRIDEX-$9.57M-$0.54N/A∞N/A-22.79%-192.95%-33.97%N/APETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)VVOSVivos Therapeutics-$13.58M-$2.91N/AN/AN/A-86.19%-335.04%-93.58%N/ALatest BLAC, PETV, VVOS, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million3/27/2025Q4 2024IRIXIRIDEX-$0.05-$0.05N/A-$0.05$12.80 million$12.70 million3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLACBellevue Life Sciences AcquisitionN/AN/AN/AIRIXIRIDEX0.551.540.85PETVPetVivo0.020.420.47VVOSVivos TherapeuticsN/A1.441.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLACBellevue Life Sciences Acquisition55.30%IRIXIRIDEX20.10%PETVPetVivo24.55%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipBLACBellevue Life Sciences Acquisition33.67%IRIXIRIDEX7.30%PETVPetVivo10.84%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLACBellevue Life Sciences AcquisitionN/A4.04 million2.68 millionNot OptionableIRIXIRIDEX12016.79 million15.42 millionOptionablePETVPetVivo2024.33 million19.06 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableBLAC, PETV, VVOS, and IRIX HeadlinesRecent News About These CompaniesVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15 at 8:04 PM | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue EstimatesMay 15 at 7:01 PM | zacks.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15 at 5:13 PM | finance.yahoo.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 15 at 2:07 AM | finance.yahoo.comVivos Therapeutics, Inc. to Release First Quarter 2025 Financial Results on May 15, 2025May 14 at 9:40 AM | quiverquant.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 14 at 9:15 AM | globenewswire.comVivos Therapeutics (VVOS) Expected to Announce Earnings on TuesdayMay 12 at 1:47 AM | americanbankingnews.comVivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comVivos to acquire sleep centerApril 17, 2025 | hmenews.comVivos Therapeutics announces agreement to acquire operating assets of SCNApril 17, 2025 | markets.businessinsider.comVivos Opens New Sleep CenterApril 16, 2025 | baystreet.caVivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in NevadaApril 16, 2025 | globenewswire.comVivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global PartnersApril 2, 2025 | markets.businessinsider.comVivos Therapeutics’ Earnings Call Highlights Growth and ExpansionApril 1, 2025 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2025 | zacks.comVivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational UpdateMarch 31, 2025 | globenewswire.com4VVOS : Earnings Outlook For Vivos TherapeuticsMarch 28, 2025 | benzinga.comVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference CallMarch 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest LoserBy Leo Miller | May 13, 2025View 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest LoserGoldman Sachs Just Revealed What’s Next for MarketsBy Gabriel Osorio-Mazilli | April 17, 2025View Goldman Sachs Just Revealed What’s Next for MarketsA 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was ReadyBy Gabriel Osorio-Mazilli | May 12, 2025View A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was ReadyBLAC, PETV, VVOS, and IRIX Company DescriptionsBellevue Life Sciences Acquisition NASDAQ:BLAC$1.21 -0.04 (-3.20%) As of 05/13/2025Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.IRIDEX NASDAQ:IRIX$1.00 0.00 (0.00%) As of 04:00 PM EasternIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.PetVivo NASDAQ:PETV$0.79 -0.07 (-7.71%) As of 02:52 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Vivos Therapeutics NASDAQ:VVOS$3.06 +0.02 (+0.66%) As of 03:59 PM EasternVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
